LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Pancreatic Cancer
Interventions
DRUG

LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan

LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02214

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01485744 - LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter